Conditions: Tonsillectomy Adenoidectomy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 74
Healthy volunteers: no

Brief summary:
Acetaminophen is frequently used as an adjunct for pain management in pediatric surgical patients. The drug is available in an over the counter, inexpensive oral form as well as a considerably more expensive intravenous form. This study will compare opioid requirements and acetaminophen plasma levels post operatively for two dosing regimens to compare oral versus intravenous routes given pre operatively.

Detailed description:
The primary purpose of this study is to compare opioid utilization in post-operative patients undergoing tonsillectomy and adenoidectomy, between IV and PO acetaminophen. Secondarily, it will provide information regarding possible cost savings, pharmacokinetics and safety between these two regimens.

Arms:
arm 1: Group 1 will receive oral acetaminophen 30mg/kg 30-60 minutes prior to scheduled surgery time . Group 1 patients will receive placebo IV infusion just prior to surgery incision. arm 2: Group 2 will receive placebo oral medication at approximately 30-60 minutes prior to scheduled surgery. Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery incision.

Interventions: intervention 1: Acetaminophen
Intervention descriptions: intervention 1: already included in arm/group descriptions

Protocol document:
Prot_SAP_000.pdf: 
PROTOCOL TITLE: Multiple Pre-operative Oral Doses Acetaminophen Versus Intravenous 
Acetaminophen 
Page 1 of 9 
 
Revised: November 18, 2016 
1) Protocol Title 
Multiple Pre-operative Oral Doses Acetaminophen Versus Intravenous Acetaminophen 
Protocol Version Date: 11/18/16 
2) Objectives 
Purpose: Acetaminophen is frequently used as an adjunct for pain management in 
pediatric surgical patients. The drug is available in an over the counter, inexpensive oral 
form as well as a considerably more expensive intravenous form. This study will compare 
opioid requirements and acetaminophen plasma levels post operatively for two dosing 
regimens to compare oral versus intravenous routes given pre operatively. 
Hypothesis: Two oral doses of acetaminophen given pre operatively provide superior 
opioid sparing effects compared to intravenous acetaminophen for pediatric tonsillectomy 
and adenoidectomy patients. 
Specific Aims: 
To compare a preoperative acetaminophen oral dosing regimen that is better than a single 
intravenous dose of acetaminophen given intraoperatively as measured by amount of 
postoperative opioid rescue pain medication given. 
To compare the cost of acetaminophen in the perioperative period for families and the 
health system. 
To evaluate acetaminophen pharmacokinetics by checking a level 1 hour and 4 hours 
after the 1st IV dose of acetaminophen or placebo. 
To evaluate the safety of this protocol. 
3) Background  
The primary purpose of this study is to compare opioid utilization, in post-operative patients 
undergoing tonsillectomy and adenoidectomy, between IV and PO acetaminophen. Secondarily, 
it will provide information regarding possible cost savings, pharmacokinetics and safety between 
these two regimens. 
A prior study conducted in cleft palate surgery patients by one of our investigators, Richard L. 
Applegate II, MD, found that total opioid dose was higher in the PO group initially1. The opioid 
amounts became similar by the third oral dose of acetaminophen. Our study design will further 
examine whether the effectiveness of oral acetaminophen is enhanced by giving multiple pre-
operative oral doses.  
Acetaminophen, otherwise known as Tylenol or Ofirmev, has been used by medical providers to 
help treat moderate to severe surgical pain in children. It is used with various medications 
including opioids or narcotics to treat pain after surgery. 
Opioids can have multiple side effects that are very serious in children after tonsillectomies and 
adenoidectomies and avoidance of intra-operative and post-operative opiates is strongly 
encouraged in tonsillectomy and adenoidectomy patients to reduce sedation and apneic events. 


PROTOCOL TITLE: Multiple Pre-operative Oral Doses Acetaminophen Versus Intravenous 
Acetaminophen 
Page 2 of 9 
 
Revised: November 18, 2016 
Studies evaluating the pharmacokinetics and pharmacodynamics of acetaminophen in children 
have measured plasma or serum concentrations, with newer studies using plasma levels.  
Plasma levels will be drawn twice from each group of patients and measured to assess 
differences in dosing. If one dosing regimen results in lower concentrations, this may help 
explain any differences found in pain scores and opioid consumption between groups. If the 
acetaminophen plasma concentration drawn during the study is less than 10 mg/L, this could 
help explain differences in post-operative pain control and opioid requirements. An oral regimen 
of 30 mg/kg x1, followed by 15 mg/kg 4 hours later, could be used to achieve concentrations 
similar to a 15 mg/kg IV dose. 
We think that two oral doses of acetaminophen given before surgery can provide better pain 
control (as measured by less need for breakthrough pain medicines like morphine or oxycodone) 
compared to one dose of intravenous acetaminophen for pediatric tonsillectomy and 
adenoidectomy patients. 
4) Inclusion and Exclusion Criteria 
The clinic schedule for pediatric ENT patients will be screened to identify patients 
scheduled for obstructive sleep apnea. Faculty surgeon, resident surgeon or the ENT 
nurse practitioner will recruit patients and complete the informed consent after review of 
patient eligibility through the inclusion/exclusion criteria: 
Inclusion Criteria: 
- 
Patients ages 4 years to 17 years scheduled for tonsillectomy and adenoidectomy 
for obstructive sleep apnea. 
Exclusion Criteria: 
- 
Patients having additional procedures or surgical interventions 
- 
Patients who meet UCDCH criteria for PICU admission: on home oxygen pre-
operatively, exhibit airway obstruction when awake (stertor above larynx, stridor 
at larynx), sleep study with apnea hypoxia index greater than 25 or sleep oxygen 
saturation nadir <80%, cardiac disease, difficult intubation 
- 
Patients with a known allergy to acetaminophen 
- 
Patients with known hepatic insufficiency or severe hepatic disease 
- 
Patients with known G6PD deficiency 
- 
Patients who are malnourished (ie lower levels of glutathione) 
- 
Patients with severe renal impairment as defined by calculated creatinine 
clearance <20 ml/min (per modified Schwarz equation) 
- 
Patients who are pregnant 
 


PROTOCOL TITLE: Multiple Pre-operative Oral Doses Acetaminophen Versus Intravenous 
Acetaminophen 
Page 3 of 9 
 
Revised: November 18, 2016 
5) Study Timelines  
Patient recruitment will occur at the Otolaryngology clinic in the days to months prior to 
surgery date. The start of active participation in the study will commence on the day of 
surgery and end after 24 hours.  The patient will take first oral study drug dose 4 hours 
prior to scheduled surgery time and remain in study for 24 hours. 
It will take approximately 24 months to enroll 80 patients if surgical volume remains the 
same as last year. However, the number of ENT surgeons increased by one and the 
surgical volume is expected to increase proportionately. 
It will take an additional 6 months to complete the primary analyses for the study. 
6) Study Endpoints 
The primary endpoint is the total dose of opioid, in morphine equivalents, that the patient 
receives for breakthrough pain in the 24 hour period following surgery. 
A secondary endpoint is the proportion of pain scores in the mild, moderate or severe 
pain ranges. 
A secondary endpoint is the peak acetaminophen level at the end of surgery, just prior to 
PACU admission. 
A secondary endpoint is the plasma acetaminophen level at 4 hours after the first IV dose 
or second oral dose. 
A secondary endpoint is the pharmacokinetics of oral vs intravenous acetaminophen. 
A safety endpoint is to identify any patient with an elevated acetaminophen plasma level 
>39 mg/L. If this threshold is reached, the next dose of acetaminophen will be held and 
liver function tests will be monitored. 
A safety endpoint is to identify any patient that reaches an acetaminophen level >99 
mg/L. At this threshold, the next acetaminophen dose will be held, liver function tests 
will be monitored, and treatment with N-acetylcysteine therapy will be initiated. 
 
7) Procedures Involved 
Patients will be randomized into two study groups by Investigational Drug Services 
(IDS). Anesthesiologists, surgeons and nurses will be blinded as to whether the child 
receives oral or intravenous acetaminophen. 
Study drugs will be prepared by IDS. The first oral medication and caregiver instructions 
will be sent home with parent at the ENT clinic visit. The first dose of oral medication 
will be given by parent prior to admission on the day of surgery. A member of the 
research team will give the parent a reminder phone call the day before the scheduled 
surgery date to ensure understanding of the drug administration and to answer any 


PROTOCOL TITLE: Multiple Pre-operative Oral Doses Acetaminophen Versus Intravenous 
Acetaminophen 
Page 4 of 9 
 
Revised: November 18, 2016 
possible questions. The ability for the research team to leave the family any voicemail 
messages is an explicit authorization within the consent form. 
Group 1 will receive oral acetaminophen 30mg/kg four hours prior to scheduled surgery 
time and second oral dose 15 mg/kg just prior to surgery (within 4 to 6 hours after the 
first dose). Group 1 patients will receive placebo IV infusion just prior to surgery 
incision. 
Group 2 will receive placebo oral medication at four hours prior to scheduled surgery and 
2nd dose placebo oral medication just prior to surgery (within 4-6 hours after the first 
dose). Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery 
incision. 
Anesthesia care will be provided per current practice at UCD Children’s Hospital and 
will include the following intraoperative pain medicines: study drug acetaminophen, IV 
dexamethasone 0.5 mg/kg to max dose of 10 mg, and fentanyl 1-2 mcg/kg. Surgery will 
proceed per current practice at UCDCH with coblation surgical technique and will 
include injection of 0.25% bupivacaine with 1:200K epinephrine to tonsillar beds. 
The first acetaminophen level will be drawn while the patient is still under anesthesia 
(less than 5 ml of blood). In most cases this will be drawn from the existing IV line. If 
unable to acquire sufficient blood draw from existing IV catheter, a needle will be used to 
draw blood from a new venous site while the child is still under anesthesia. 
The second acetaminophen level will be drawn 4 hours after IV administration of placebo 
or acetaminophen study drug. If blood cannot be drawn from the IV catheter, the patient 
and parent will be given the option to have level drawn from a new venous site or decline 
the test. Patients can remain in the study without the second acetaminophen draw and will 
be analyzed on an intention to treat basis. If the first acetaminophen level is high and the 
second level has been declined, then the admitting physicians will address this by holding 
the next acetaminophen dose and proceeding with standard of care. 
Given the evidence established in the literature review, it is highly unlikely that a 
patient’s acetaminophen level will reach the high threshold level of 40mg/L. Though we 
do not believe the patient is at more than minimal risk, we have established a safety 
monitoring plan for plasma levels as described in section 10. 
The Wong Baker Faces scale will be used to obtain pain scores in PACU (post anesthesia 
care unit) and on the ward, and results will be recorded in the EMR. This scale is 
currently used by nurses in the UC Davis Children’s Hospital and available on EMR. 
Pain medicines will be given per usual practice at UCDCH with 0.025mg/kg IV 
morphine for pain scores 4-10 using standardized order sets in the PACU. Oral doses of 
ibuprofen 10 mg/kg will be given 3 hours after the IV acetaminophen study drug and 
continued every 6 hours around the clock. Oral acetaminophen 15 mg/kg will be given 
every 6 hours around the clock following the IV acetaminophen study drug. On the ward, 


PROTOCOL TITLE: Multiple Pre-operative Oral Doses Acetaminophen Versus Intravenous 
Acetaminophen 
Page 5 of 9 
 
Revised: November 18, 2016 
the usual practice at UCDCH will be used for analgesia for study patients. The ENT in 
house resident will be called for breakthrough pain not controlled by ibuprofen and 
acetaminophen scheduled doses (around the clock). If contacted, the in house resident 
will select the oxycodone pediatric order set as follows: oxycodone 0.05 mg/kg po every 
4 hours for pain scores 4-6, oxycodone 0.1 mg/kg po every 4 hours for pain scores 7-10. 
Breakthrough pain medicine will be recorded in the EMR. 
The majority of data will be collected from participants during the first 24 hours. 
Following discharge, the chart will be accessed to record potential complications related 
to the study drug and identify length of stay. 
Anticipated Timeline for a Surgery Scheduled at 11:30 
07:00   
30 mg/kg 1st po loading dose or placebo at home 
11:00   
15 mg/kg 2nd po or placebo  
(2nd po dose will be given in pre-op unit 20-30 mins prior to induction and such that it is 
between 4 and 6 hours after the first dose to allow flexibility of surgery schedule) 
11:30  
IV dose or placebo as soon as IV started prior to incision 
12:30  
Draw first acetaminophen level from IV at end of surgery 
15:30 
Draw second level 4 hours after IV dose  
 
17:30  
15mg/kg po all patients per current practice 
23:30  
15 mg/kg all patients… and every 6 hours until discharge per current practice 
 
Dosing Rationale for Oral and IV Acetaminophen 
Oral acetaminophen will be administered in two pre-operative doses: a 30 mg/kg (maximum 
1000 mg) loading dose approximately 4-6 hours prior to the start of surgery, and by a 15 mg/kg 
(maximum 1000 mg) 4-6 hours after the first dose, at the time of general anesthesia. Similar 
regimens have been shown to achieve therapeutic effect more quickly than standard maintenance 
dosing of 10-15 mg/kg every 4-6 hours2-5. Regimens including oral loading doses of 20-40 mg/kg 
have not resulted in acetaminophen toxicity.5-7 
Intravenous acetaminophen will be administered as a single pre-operative dose, 15 mg/kg 
(maximum 1000 mg) at the time of general anesthesia. This is the most commonly studied and 
generally accepted pediatric intravenous dose.7 


PROTOCOL TITLE: Multiple Pre-operative Oral Doses Acetaminophen Versus Intravenous 
Acetaminophen 
Page 6 of 9 
 
Revised: November 18, 2016 
 
The total dose of acetaminophen during the study period will be 90 mg/kg in the oral group and 
60 mg/kg in the IV group. Previous publications have recommended maximum daily doses of 75 
or 90 mg/kg/day, particularly to allow for single loading doses4, 9-12.  
 
8) Data and/or Specimen Management and Confidentiality 
Statistical analysis plan 
The primary outcome measure is the between group difference in total opioid 
administration in the first 24 hours after surgery. The groups will be compared for 
similarity of age, sex, weight, and percentile weight on standard growth charts to ensure 
adequate randomization. Data will be tested for normal distribution and analyzed by t-test 
or Wilcoxon rank sum test as appropriate; p<0.05 will be considered statistically 
significant. For this study a difference of 100 mcg/kg morphine equivalents would be 
considered clinically significant. Sample size was calculated size based on results from a 
prior study.1 The assumptions for this calculation are: 
• 
Alpha 0.05  
• 
Power 0.9 
• 
Overall supplemental opioid (morphine equivalents, mcg/kg) found in the prior 
study; defining clinically significant difference to be 100 mcg/kg of rescue opioid 
and assuming a normal distribution:  
o IV: 273 ± 110 
o Oral: 377 ± 136 
• 
Sample size to detect difference 63 
To allow for early withdrawal, we propose to enroll 80 patients. A planned interim 
analysis will be conducted after 40 patients have been enrolled to allow us to refine 
the sample size calculation if needed. 
Secondary outcome measures will include between group differences in: 
• The proportion of pain scores showing severe or mild pain 
• The number of patients requiring no opioid administration after surgery 
• The prevalence of side effects such as nausea and vomiting 
• The number of patients and total number of episodes of respiratory depression 
requiring treatment 
• Acetaminophen levels determined at surgery end and 4 hours after the first IV 
dose or second oral dose 
• The number of patients with acetaminophen levels above the safety endpoint 
• Acetaminophen pharmacokinetics calculated from patients in whom 2 levels are 
obtained  
• Intra-operative opioid dose of fentanyl in mcg/kg/hour 


PROTOCOL TITLE: Multiple Pre-operative Oral Doses Acetaminophen Versus Intravenous 
Acetaminophen 
Page 7 of 9 
 
Revised: November 18, 2016 
Blood/Data Management and Confidentiality 
 
Blood samples obtained for acetaminophen level determination will be handled following 
UCDMC policies and procedures. Residual blood from those samples will be stored per 
Laboratory standard operating procedures until determination that no further testing is needed for 
individual patients. 
 
Laboratory REDCap will be used as a data collection and management system for the study. As 
such, there are no plans to physically transfer data from one researcher to the next; ie, data is 
accessible through logging into REDCap’s secured database and not via the handing off a 
secured flashdrive. 
 
Source documents will be stored in a locked cabinet within the department of Anesthesiology 
and Pain Medicine when not used by the investigators.  
 
All research staff have completed his/her CITI training, and are knowledgeable surrounding 
aspects of confidentiality. 
 
Human Research records, including signed and dated consent documents, will be maintained for 
at least 7 years after the child reaches 18 years of age. Signed and dated HIPAA authorizations 
will be kept for at least 6 years after completion of the research.  
 
9) Provisions to Monitor the Data to Ensure the Safety of Subjects 
 
According to the Rumack-Matthew Nomogram, patients are at risk for hepatic toxicity when the 
acetaminophen plasma concentration exceeds 100 mcg/mL (100 mg/L) 4-5 hours after an acute 
ingestion, and treatment with n-acetylcysteine should be initiated.13 Based on population 
pharmacokinetics, the dosing regimens used in this study are expected to yield maximum 
acetaminophen plasma concentrations of 15-20 mcg/mL, well below the levels associated with 
toxicity.2,13 Based on this information, the following safety monitoring protocol will be utilized 
in this study: 
Two acetaminophen levels will be obtained during surgery: the first will be drawn 1 hour after 
administration of the IV dose (or IV placebo), and the second will be drawn 3 hours later (4 
hours after the IV dose). These specimens will be delivered to the lab, and results will be 
reported in the EMR prior to the next dose of acetaminophen. The pediatric pharmacist will 
monitor the second (4-hour) level and contact the ENT resident on call and the bedside nurse to 
recommend the appropriate intervention as follows: 
 
• Acetaminophen level > 100 mg/L à discontinue acetaminophen, monitor liver function tests 
(LFTs), initiate N-acetylcysteine therapy 
• Acetaminophen level 40 – 99 àhold next acetaminophen dose, monitor LFTs; ENT and 
pharmacy team to determine when and how to re-dose 
• Acetaminophen level 0 – 39 à no intervention needed 
Acetaminophen levels will not be blinded and will appear in the EMR. 


PROTOCOL TITLE: Multiple Pre-operative Oral Doses Acetaminophen Versus Intravenous 
Acetaminophen 
Page 8 of 9 
 
Revised: November 18, 2016 
10) Withdrawal of Subjects 
Subjects who refuse to swallow the oral medication will be withdrawn from research. 
11) Risks to Subjects 
Parents will be asked to give a pain medicine at home prior to surgery. The blood draws 
will be done from the existing IV for most patients and will be no more than 5 ml per 
draw. If the IV cannot be drawn back from then a new venipuncture will be performed 
while the child is under anesthesia. For the level on the ward, the patient will be given the 
option to decline a blood draw if the IV does not draw back for the sample and remain in 
the study. 
12) Potential Benefits to Subjects 
The patient may have better pain control if enrolled in the study. 
13) Provisions to Protect the Privacy Interests of Subjects 
The faculty surgeon, faculty ENT attendings, ENT residents, nurse practitioner and/or 
ENT clinical research coordinator will identify potential participants via the use of the 
requested IRB HIPAA Waiver for Authorization for participant identification and 
recruitment. From the list of ENT patients scheduled for clinic visits for obstructive sleep 
apnea, they will access EMR to screen for eligible participants. 
They will discuss the study and allow for pertinent questions and concerns to be 
addressed and answered before obtaining assent of the patient and consent from the 
appropriate family member to minimize the number of outside interactions for 
conducting the study. 
14) Drugs or Devices 
☒ I confirm that all investigational drugs will be received by the Investigational Drug Service 
(IDS).  The IDS will store, handle, and administer those drugs so that they will be used only 
on subjects and be used only by authorized investigators. 
 
☐ I confirm that all investigational devices will be labelled in accordance with FDA regulations 
and stored and dispensed in such a manner that they will be used only on subjects and be used 
only by authorized investigators. 
 
 
 
References 
 
1.  
Nour C, Ratsiu J, Singh N, et al.Analgesic effectiveness of acetaminophen for primary 
cleft palate repair in young children: a randomized placebo controlled trial.Paediatr 
Anaesth2014;24:574–81 
2. 
de Martino M, Chiarugi A. Recent Advances in Pediatric Use of Oral Paracetamol in 
Fever and Pain Management. Pain and Therapy 2015;4:149-68. 
3. 
Gibb IA, Anderson BJ. Paracetamol (acetaminophen) pharmacodynamics: interpreting 
the plasma concentration.  Arch Dis Child. England2008:241-7. 


PROTOCOL TITLE: Multiple Pre-operative Oral Doses Acetaminophen Versus Intravenous 
Acetaminophen 
Page 9 of 9 
 
Revised: November 18, 2016 
4. 
Shann F. Paracetamol: when, why and how much. J Paediatr Child Health 1993;29:84-5. 
5. 
Treluyer JM, Tonnelier S, d'Athis P, Leclerc B, Jolivet-Landreau I, Pons G. Antipyretic 
efficacy of an initial 30-mg/kg loading dose of acetaminophen versus a 15-mg/kg maintenance 
dose. Pediatrics 2001;108:E73. 
6. 
Romsing J, Ostergaard D, Senderovitz T, Drozdziewicz D, Sonne J, Ravn G. 
Pharmacokinetics of oral diclofenac and acetaminophen in children after surgery.  Paediatr 
Anaesth. France2001:205-13. 
7. 
Anderson BJ, Holford NH, Woollard GA, Kanagasundaram S, Mahadevan M. 
Perioperative pharmacodynamics of acetaminophen analgesia in children. Anesthesiology 
1999;90:411-21. 
8. 
Jahr JS, Lee VK. Intravenous acetaminophen.  Anesthesiol Clin. United States: 2010 
Elsevier Inc; 2010:619-45. 
9. 
Anderson BJ. What we don't know about paracetamol in children. Paediatr Anaesth 
1998;8:451-60. 
10. 
Temple AR. Pediatric dosing of acetaminophen. Pediatric pharmacology (New York, 
NY) 1983;3:321-7. 
11. 
Kleiber C. Acetaminophen dosing for neonates, infants, and children.  J Spec Pediatr 
Nurs. United States2008:48-9. 
12. 
van der Marel CD, van Lingen RA, Pluim MA, et al. Analgesic efficacy of rectal versus 
oral acetaminophen in children after major craniofacial surgery.  Clin Pharmacol Ther. United 
States2001:82-90. 
13. 
Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics 
1975;55:871-6. 
 

ICF_001.pdf: 
Permission to Take Part in a Human Research Study 
Page 1 of 8 
For IRB Use 
Document Revision DateJuly,10,2017 
Protocol Version Date 8/2/2017 
Title of research study: 
Modified Pre-operative Oral Doses Acetaminophen Versus Intravenous Acetaminophen 
Investigator: Cathy R. Lammers, MD 
Why am I being invited to take part in a research study? 
We invite you to take part in a research study because your child is scheduled for a tonsillectomy and 
adenoidectomy. 
What should I know about a research study? 
(Experimental Subject's Bill of Rights) 
x
Someone will explain this research study to you, including:
o
The nature and purpose of the research study.
o
The procedures to be followed.
o
Any drug or device to be used.
o
Any common or important discomforts and risks.
o
Any benefits you might expect.
x
Whether or not you take part is up to you.
x
You can choose without force, fraud, deceit, duress, coercion, or undue influence.
x
You can choose not to take part.
x
You can agree to take part now and later change your mind.
x
Whatever you decide it will not be held against you.
x
You can ask all the questions you want before you decide.
x
If you agree to take part, you will be given a signed and dated copy of this document.
Who can I talk to? 
If you have questions, concerns, or complaints, or think the research has hurt you, talk to the research 
team. During business hours, contact: 
Ana Arias, Department of Anesthesiology 916-703-5456 
Ahmed Bayoumi, Department of Otolaryngology 916-734-2863 
For non-emergency issues you can call the UCDMC Hospital Operator (916-734-2011), tell the 
Operator you are participating in a research study and you wish to talk to the anesthesiologist on- call or 
the otolaryngologist on-call (24 hours a day/ 7 days a week). In the case of an emergency, dial 911 from 
any phone. 
APPROVED by the Institutional Review Board 
at the University of California, Davis 
Protocol 
Approved 
 
 
948256
08/02/2017


Permission to Take Part in a Human Research Study 
Page 2 of 8 
For IRB Use 
Document Revision DateJuly,10,2017 
Protocol Version Date 8/2/2017 
 
 
 
 
 
 
 
 
 
This research has been reviewed and approved by an Institutional Review Board (“IRB”). Information to 
help you understand research is on-line at http://www.research.ucdavis.edu/policiescompliance/irb-   
admin/.You may talk to a IRB staff member at (916) 703-9151, hs-irbadmin@ucdavis.edu, or 2921 
Stockton Blvd, Suite 1400, Room 1429, Sacramento, CA 95817 for any of the following: 
 
x Your questions, concerns, or complaints are not being answered by the research team. 
x You cannot reach the research team. 
x You want to talk to someone besides the research team. 
x You have questions about your rights as a research subject. 
x You want to get information or provide input about this research. 
 
Why is this research being done? 
The purpose of the study is to compare pain control between two forms of acetaminophen, and to 
possibly save money for future patients who have to undergo the same surgery as your child. 
 
Acetaminophen, otherwise known as Tylenol or Ofirmev, has been used by medical providers to help 
treat moderate to severe surgical pain in children. It is used with various medications including opioids 
or narcotics to treat pain after surgery. Opioids/narcotics are strong morphine-like medicines that can 
have multiple side effects that can be very serious in children after tonsillectomies and adenoidectomies 
(for example: slower breathing rates, sedation, and obstruction). 
 
Because of this, there is interest in the use of acetaminophen to manage surgical pain. Other studies have 
shown that if acetaminophen is given to a child, then the child will need less of these stronger pain 
medications to be comfortable after surgery. Acetaminophen comes in various forms including an 
inexpensive oral form (Tylenol) and a more expensive intravenous (IV) form (Ofirmev). 
 
We think that one loading oral dose of acetaminophen given before surgery can provide better pain 
control (as measured by less need for morphine-like medicine) compared to one dose of intravenous 
acetaminophen for pediatric tonsillectomy and adenoidectomy patients. 
 
How long will the research last? 
We expect that your child will be in this research study beginning approximately 1  hour before surgery 
and continuing for approximately 24 hours after surgery. 
 
How many people will be studied? 
We expect about 80 children will be in this research study at the UC Davis Children’s Hospital. 
APPROVED by the Institutional Review Board 
at the University of California, Davis 
Protocol 
Approved 
 
 
948256
08/02/2017


Permission to Take Part in a Human Research Study 
Page 3 of 8 
For IRB Use 
Document Revision DateJuly,10,2017 
Protocol Version Date 8/2/2017 
 
 
 
 
 
 
 
 
 
What happens if I say yes, I want to be in this research? 
All patients will receive acetaminophen. The treatment your child gets will be chosen by chance, like 
flipping a coin. Neither you nor the study doctor will choose what treatment your child gets. Your child 
will have a 50:50 chance of being given each treatment. 
 
Group 1 will take the acetaminophen by mouth in one dose before surgery. Group 2 will receive their 
acetaminophen in the operating room before surgery through the IV. After the surgery, both groups will 
receive acetaminophen in the same way, by mouth. The pharmacists who have prepared the medications 
for us will know which group you have been assigned to and whether the acetaminophen was given by 
mouth or by IV. Your doctors, however, will not know which route the acetaminophen was given. To 
make sure no one other than the pharmacist knows which group you are in, there will be placebo doses. 
A placebo dose by mouth is plain flavored syrup made to look just like the liquid acetaminophen. A 
placebo will also be used to look like the IV acetaminophen. Your child will definitely receive 
acetaminophen but in group 1 it will be by mouth and in group 2 it will be through the IV. 
 
 
 
Every patient in both groups will take medicine (acetaminophen or placebo) by mouth prior to surgery. 
 
As part of the study, one set of acetaminophen blood levels will be drawn while your child is still under 
anesthesia and another set will be drawn 3 hours after the IV drug was given. Your child will be awake 
for the second draw but in most cases this can be done by pulling the blood sample back through the IV 
without a needle poke. 
 
Your child will be shown the Wong Baker Faces scale to obtain pain scores. He/she will be given pain 
medicines in recovery room and in their hospital room per our usual practices at UC Davis Children’s 
Hospital. 
 
What are my responsibilities if I take part in this research? 
If you take part in this research, you will be responsible for attending your scheduled surgery at 
the UC Davis children surgery center.  
 
What happens if I do not want to be in this research? 
You may decide not to take part in the research and it will not be held against you
APPROVED by the Institutional Review Board 
at the University of California, Davis 
Protocol 
Approved 
 
 
948256
08/02/2017


Permission to Take Part in a Human Research Study 
Page 4 of 8 
For IRB Use 
Document Revision DateJuly,10,2017 
Protocol Version Date 8/2/2017 
 
 
If you decide not to have your child participate in this study, his/her surgery will go on as planned. 
 
What happens if I say yes, but I change my mind later? 
You can leave the research at any time and it will not be held against you. 
 
Is there any way being in this study could be bad for me? 
Participating in this study exposes your child to minimal additional risk. The surgery and anesthesia that 
your child is undergoing may have other risks, which your physicians will explain to you separately. 
 
 
Acetaminophen is available over the counter and is considered to be safe for use in children, with few 
side effects. However, as with all drugs, side effects have been reported and include nausea, rash, and 
headache. Children who received intravenous acetaminophen have also reported to have had side effects 
of nausea, vomiting, itching and agitation. Other rare side effects following intravenous acetaminophen 
that have been reported in clinical studies include decreased blood count, abdominal pain, diarrhea, 
injection site pain, peripheral swelling, fever, elevated liver enzymes, increased blood volume, muscle 
spasms, pain in legs or arms, headache, loss of or altered sleep, decreased urine output, fluid in or 
around the lungs, swelling around the eyes, rash, and high or low blood pressure. Very rare but severe 
reactions include liver injury or toxicity, kidney damage, allergic reactions and death. This has been 
rarely reported when acetaminophen has been given within the recommended dose. 
 
The blood draws that will be part of this study will be obtained from existing IV sites. If the IV cannot 
be drawn, a single venipuncture (needle poke) will be performed while your child is still under 
anesthesia. For the second acetaminophen blood level, which is drawn when your child is awake, we 
will most likely be able to draw it back from the existing IV without a needle poke. If his/her IV no 
longer works, you have the option to have the blood drawn with a small needle or decline this test and 
still remain in the study. 
 
Abnormal Test Results 
 
It is unlikely that there will be any abnormal results from the blood draws. We have designed the study 
to make this risk small. However, if a lab result for the blood level of study drug/ acetaminophen is 
abnormal then we will notify the ENT physician that will be taking care of your child while he/she is at 
the hospital. We will also notify your child’s bedside nurse. If the blood level is high then we will hold 
the next dose of acetaminophen. You will be made aware of this and a different pain medicine will be 
used if needed. 
APPROVED by the Institutional Review Board 
at the University of California, Davis 
Protocol 
Approved 
 
 
948256
08/02/2017


Permission to Take Part in a Human Research Study 
Page 5 of 8 
For IRB Use 
Document Revision DateJuly,10,2017 
Protocol Version Date 8/2/2017 
 
 
 
 
 
 
 
 
 
If there are any other abnormal test results that are discovered, you will be informed about these results 
and recommend you contact your private medical provider for follow-up. Please be advised that as 
researchers, we are not trained to diagnose or treat all medical conditions. You or your insurance 
company will be responsible for payment of any treatment of medical conditions. 
 
Will being in this study help me in any way? 
We cannot promise any benefits to you or others from your taking part in this research. However, 
possible benefits include better pain control. 
 
What happens to the information collected for the research? 
Efforts will be made to limit use or disclosure of your personal information, including research study 
and medical records, to people who have a need to review this information. We cannot promise 
complete confidentiality. Organizations that may inspect and copy your information include the IRB and 
other University of California representatives responsible for the management or oversight of this study. 
During your participation in this research, data will be collected about you. The de-identified data and 
any specimens, such as blood or tissue that are taken from you for this study, they will become the 
property of the University of California. The specimens may be used in this research, may be used in 
other research, and may be shared with other organizations. The specimens could lead to discoveries or 
inventions that may be of value to the University of California or to other organizations. Under state law 
you do not have any right to money or other compensation stemming from products that may be 
developed from the specimens. 
If you agree to share the biological specimen(s) collected from you, please initial here.   
 
The sponsor, monitors, auditors, the IRB, the Food and Drug Administration will be granted direct 
access to your research records to conduct and oversee the study. We may publish the results of this 
research. However, we will keep your name and other identifying information confidential. 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. 
Law. This Web site will not include information that can identify you. At most, the Web site will 
include a summary of the results. You can search this Web site at any time. 
If we access protected health information (e.g., your medical record), you will be asked to sign a 
separate form to give your permission. 
Federal law provides additional protections of your medical records and related health information. 
These are described in the UC Davis Health System Notice of Privacy Practices 
(http://www.ucdmc.ucdavis.edu/compliance/pdf/notice.pdf) and in an attached document. 
APPROVED by the Institutional Review Board 
at the University of California, Davis 
Protocol 
Approved 
 
 
948256
08/02/2017


Permission to Take Part in a Human Research Study 
Page 6 of 8 
For IRB Use 
Document Revision DateJuly,10,2017 
Protocol Version Date 8/2/2017 
 
 
 
 
 
 
 
 
 
Can I be removed from the research without my OK? 
The person in charge of the research study or the sponsor can remove you from the research study 
without your approval. Possible reasons for removal include: 
x 
It is in your child’s best interest to be removed 
x 
Your child experiences a study – related injury 
x 
Your child needs an additional or different medication/treatment 
x 
You or your child do not comply with the study plan 
x 
Administrative and/or medical reasons 
 
We will tell you about any new information that may affect your health, welfare, or choice to stay in the 
research. 
 
What else do I need to know? 
You or your health plan will be billed for the costs of routine medical care you receive during the study. 
These costs may include operating room fees, pharmacy charges, treatments, hospitalization, scans, etc. 
You will be expected to pay for the usual deductibles and co-payments, and for any routine care that is 
not covered. 
Only the costs of research or experimental procedures will be paid by the study. This includes the cost of 
the acetaminophen and the cost of processing blood work for acetaminophen levels. 
For more information about possible costs, please contact the research team. The research team can 
follow UC Davis Uninsured Non-Emergency Estimate Policy (Policy ID 1883) to work with their 
department and Decision Support Services to get you a cost estimate. 
It is important that you promptly tell the person in charge of the research if you believe that you have 
been injured because of taking part in this study. If you are injured as a result of being in this study, the 
University of California will provide necessary medical treatment. Depending on the circumstances, the 
costs of the treatment may be covered by University or the study sponsor or may be billed to your 
insurance company just like other medical costs. The University and the study sponsor do not normally 
provide any other form of compensation for injury.  For more information about compensation, you may 
call the IRB Administration at (916) 703-9151 or email at HS-IRBAdmin@ucdavis.edu. 
You will not be compensated for taking part in this study. 
APPROVED by the Institutional Review Board 
at the University of California, Davis 
Protocol 
Approved 
 
 
948256
08/02/2017


Permission to Take Part in a Human Research Study 
Page 7 of 8 
For IRB Use 
Document Revision DateJuly,10,2017 
Protocol Version Date 8/2/2017 
 
 
 
 
 
 
 
 
 
Signature Block for Children 
Your signature documents your permission for the named child to take part in this research. 
 
 
 
Printed name of child 
 
 
  
 
Signature of parent or individual legally authorized to consent to the 
child’s general medical care 
 
 Parent 
Date 
  
Individual legally authorized to 
Printed name of parent or individual legally authorized to consent to the 
child’s general medical care 
consent to the child’s general 
medical care (See note below) 
 
 
 
 I allow the research team to leave me research – related voicemail messages. 
 
 
 Obtained 
 Not obtained because the capability of the child is so limited that the child cannot reasonably be consulted. 
 Waived by the IRB because the intervention or procedure involved in the research holds out a prospect of direct 
benefit that is important to the health or well-being of the child and is available only in the context of the research. 
 
 
 
  
 
Signature of person obtaining consent and assent 
Date 
 
 
 
Printed name of person obtaining consent 
Assent 
APPROVED by the Institutional Review Board 
at the University of California, Davis 
Protocol 
Approved 
 
 
948256
08/02/2017


Permission to Take Part in a Human Research Study 
Page 8 of 8 
For IRB Use 
Document Revision DateJuly,10,2017 
Protocol Version Date 8/2/2017 
 
 
 
 
 
 
 
 
 
My signature below documents that the information in the consent document and any other written information was 
accurately explained to, and apparently understood by, the subject, and that consent was freely given by the subject. 
Signature of witness to consent process 
Date 
Printed name of person witnessing consent process 
 
APPROVED by the Institutional Review Board 
at the University of California, Davis 
Protocol 
Approved 
 
 
948256
08/02/2017